Literature DB >> 32337818

Diagnostic accuracy of FibroScan-AST score to identify non-alcoholic steatohepatitis with significant activity and fibrosis in Japanese patients with non-alcoholic fatty liver disease: Comparison between M and XL probes.

Satoshi Oeda1,2, Hirokazu Takahashi3, Kento Imajo4, Yuya Seko5, Takashi Kobayashi4, Yuji Ogawa4, Michihisa Moriguchi5, Masato Yoneda4, Keizo Anzai3, Hiroyuki Irie6, Eisaburo Sueoka2,7, Shinichi Aishima8, Masayoshi Kage9, Yoshito Itoh5, Yuichiro Eguchi1, Atsushi Nakajima4.   

Abstract

AIM: Recently, FibroScan-AST (FAST) score was reported to be effective for identifying non-alcoholic steatohepatitis (NASH) with significant activity and fibrosis in non-alcoholic fatty liver disease (NAFLD). The aim of this study was to confirm the diagnostic accuracy of FAST score of Japanese patients and compare the cut-off values and diagnostic accuracy between the FibroScan M and XL probes.
METHODS: Eighty-two and 84 patients were included the verification and validation sets, respectively. All patients were diagnosed with NAFLD by biopsy by two central expert pathologists. Liver stiffness measurements and controlled attenuation parameter were carried out, and diagnostic performance was evaluated using receiver operating characteristic (ROC) curve analysis.
RESULTS: No significant difference existed in FAST score between the M and XL probes (0.489 vs. 0.483, P = 0.187). No significant difference existed in the area under the ROC between the two probes (M, 0.7598; XL, 0.7614; P = 0.958). According to the Youden index, the cut-off value using the M probe was 0.57 with 68.2% sensitivity and 78.3% specificity. For the XL probe, the cut-off value was 0.56 with 68.2% sensitivity and 73.3% specificity. To obtain sensitivity and specificity values higher than 90%, cut-off values of 0.35 and 0.66 were chosen for the M probe and 0.32 and 0.63 were chosen for the XL probe.
CONCLUSIONS: There was no significant difference in diagnostic accuracy of FAST score between the FibroScan M and XL probes. The FAST score can be used to identify NASH with significant risk in Japanese patients regardless of probe selection. ©2020 The Japan Society of Hepatology.

Entities:  

Keywords:  elastography; fibrosis; non-alcoholic fatty liver disease activity score; non-alcoholic steatohepatitis; steatosis

Year:  2020        PMID: 32337818     DOI: 10.1111/hepr.13508

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  9 in total

1.  Non-alcoholic Fatty Liver Disease and Depression: Evidence for Genotype × Environment Interaction in Mexican Americans.

Authors:  Eron Grant Manusov; Vincent P Diego; Khalid Sheikh; Sandra Laston; John Blangero; Sarah Williams-Blangero
Journal:  Front Psychiatry       Date:  2022-07-01       Impact factor: 5.435

2.  Validation and Performance of FibroScan®-AST (FAST) Score on a Brazilian Population with Nonalcoholic Fatty Liver Disease.

Authors:  Ana Carolina Cardoso; Cristiane Valle Tovo; Nathalie Carvalho Leite; Ibrahim A El Bacha; Fernanda Luiza Calçado; Gabriela Perdomo Coral; Glauco Navas Sammarco; Claudia Cravo; Roberto José Carvalho Filho; Renata de Mello Perez; Ronir Raggio Luiz; Edison Roberto Parise; Cristiane A Villela-Nogueira
Journal:  Dig Dis Sci       Date:  2022-01-29       Impact factor: 3.487

3.  Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms.

Authors:  Tinsay A Woreta; Mark L Van Natta; Mariana Lazo; Arunkumar Krishnan; Brent A Neuschwander-Tetri; Rohit Loomba; Anna Mae Diehl; Manal F Abdelmalek; Naga Chalasani; Samer Gawrieh; Srinivasan Dasarathy; Raj Vuppalanchi; Mohammad S Siddiqui; Kris V Kowdley; Arthur McCullough; Norah A Terrault; Cynthia Behling; David E Kleiner; Mark Fishbein; Paula Hertel; Laura A Wilson; Emily P Mitchell; Laura A Miriel; Jeanne M Clark; James Tonascia; Arun J Sanyal
Journal:  PLoS One       Date:  2022-04-15       Impact factor: 3.752

4.  Distribution of FIB-4 index in the general population: analysis of 75,666 residents who underwent health checkups.

Authors:  Aya Sugiyama; Akemi Kurisu; Bunthen E; Serge Ouoba; Ko Ko; Anvarjon Rakhimov; Tomoyuki Akita; Takayuki Harakawa; Toru Sako; Makoto Koshiyama; Takashi Kumada; Junko Tanaka
Journal:  BMC Gastroenterol       Date:  2022-05-13       Impact factor: 2.847

Review 5.  The Use of Transient Elastography Technology in the Bariatric Patient: a Review of the Literature.

Authors:  Max M Puthenpura; Vishal Patel; John Fam; Leon Katz; David S Tichansky; Stephan Myers
Journal:  Obes Surg       Date:  2020-09-26       Impact factor: 4.129

6.  Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis.

Authors:  Tadashi Namisaki; Kosuke Kaji; Naotaka Shimozato; Daisuke Kaya; Takahiro Ozutsumi; Yuki Tsuji; Yukihisa Fujinaga; Koh Kitagawa; Masanori Furukawa; Shinya Sato; Yasuhiko Sawada; Norihisa Nishimura; Hiroaki Takaya; Yasushi Okura; Kenichiro Seki; Hideto Kawaratani; Kei Moriya; Ryuichi Noguchi; Kiyoshi Asada; Takemi Akahane; Akira Mitoro; Hitoshi Yoshiji
Journal:  Indian J Gastroenterol       Date:  2022-03-12

Review 7.  Epidemiology: Pathogenesis, and Diagnostic Strategy of Diabetic Liver Disease in Japan.

Authors:  Yoshio Sumida; Toshihide Shima; Yasuhide Mitsumoto; Takafumi Katayama; Atsushi Umemura; Kanji Yamaguchi; Yoshito Itoh; Masashi Yoneda; Takeshi Okanoue
Journal:  Int J Mol Sci       Date:  2020-06-18       Impact factor: 5.923

8.  Effect of 48-week pemafibrate on non-alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan-aspartate aminotransferase score.

Authors:  Takeshi Hatanaka; Takashi Kosone; Naoto Saito; Satoshi Takakusagi; Hiroki Tojima; Atsushi Naganuma; Hitoshi Takagi; Toshio Uraoka; Satoru Kakizaki
Journal:  JGH Open       Date:  2021-08-28

9.  Comparison of FibroScan-Aspartate Aminotransferase (FAST) Score and Other Non-invasive Surrogates in Predicting High-Risk Non-alcoholic Steatohepatitis Criteria.

Authors:  Jae Seung Lee; Hye Won Lee; Beom Kyung Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Jae Young Jang; Soo Young Park; Hyun Woong Lee; Chun Kyon Lee; Seung Up Kim
Journal:  Front Med (Lausanne)       Date:  2022-04-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.